Table 4.
Clinical status at day 14 by pathogen in PWID and non-PWID patients in the clinically evaluable population.
| PWID | Non-PWID | |||
|---|---|---|---|---|
| Pathogen, n/N (%) | Dalbavancin Single-dose | Dalbavancin 2-dose | Dalbavancin Single-dose | Dalbavancin 2-dose |
| Staphylococcus aureus | 36/40 (90.0) | 45/49 (91.8) | 76/83 (91.6) | 86/88 (97.7) |
| MRSA | 15/16 (93.8) | 26/29 (89.7) | 14/16 (87.5) | 22/23 (95.7) |
| MSSA | 21/24 (87.5) | 20/21 (95.2) | 62/67 (92.5) | 64/65 (98.5) |
| Streptococcus agalactiae | 0 (0) | 0 (0) | 3/3 (100) | 2/3 (66.7) |
| Streptococcus anginosus group | 21/26 (80.8) | 13/13 (100) | 3/3 (100) | 2/2 (100) |
| Streptococcus anginosus | 2/3 (66.7) | 0 (0) | 2/2 (100) | 1/1 (100) |
| Streptococcus constellatus | 7/8 (87.5) | 4/4 (100) | 0 (0) | 1/1 (100) |
| Streptococcus intermedius | 12/15 (80) | 9/9 (100) | 1/1 (100) | 0 (0) |
| Streptococcus dysgalactiae | 0 (0) | 0 (0) | 3/3 (100) | 3/3 (100) |
| Streptococcus pyogenes | 2/2 (100) | 2/3 (66.7) | 10/11 (90.9) | 14/15 (93.3) |
| Enterococcus faecalis | 0 | 0 | 3/3 (100) | 7/7 (100) |
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PWID, persons who inject drugs.